EPISODE · Feb 20, 2019 · 35 MIN
UniQure
from Help 4 HD Live! · host Help 4 HD Live!
Dr. Higgins is the Vice President of Clinical Development at uniQure. He is responsible for the early development of clinical gene therapy trials for neurological disorders. Prior to joining uniQure in 2018, Dr. Higgins was responsible for all neurological diagnostic testing at Quest Diagnostics and was the federal CLIA-license holder for a specialty laboratory. He was formerly a Professor at Weill Cornell Medical College where he was the principal investigator on several private foundation and NIH research grants focused on clinical neurogenetics. He held senior leadership positions in genomic medicine at the federal and state governments including the National Institute of Health (NIH) and the New York State Department of Health (NYSDOH). At NIH he was part of the Human Genome Project and teams that initiated the first-in-human enzyme replacement and gene therapy clinical trials. He led the Human Genetic Initiative at the NYSDOH. He discovered the genes or loci for several diseases including Parkinson disease, essential tremor, ataxia, intellectual disability (ID), and metabolic disorders. He is a fellow of the American Academy of Neurology with board certifications in Pediatrics by the American Board of Pediatrics and Neurology with Special Qualification in Child Neurology by the American Board of Psychiatry and Neurology. He has authored more than 100 peer-reviewed publications, book chapters, and reviews articles in the field of neurogenetics. He is licensed to practice medicine in MA and NY. Dr. Higgins earned his bachelor’s degree in biology from Marist College and medical degree from New York University. He completed residences in Pediatrics at Children’s Hospital/Harvard Medical School; Adult Neurology at NYU/Bellevue; and Child Neurology at Children’s National Medical Center/George Washington University. He completed a 3-year fellowship program at NIH in neurogenetics and metabolic neurology.
What this episode covers
Dr. Higgins is the Vice President of Clinical Development at uniQure. He is responsible for the early development of clinical gene therapy trials for neurological disorders. Prior to joining uniQure in 2018, Dr. Higgins was responsible for all neurological diagnostic testing at Quest Diagnostics and was the federal CLIA-license holder for a specialty laboratory. He was formerly a Professor at Weill Cornell Medical College where he was the principal investigator on several private foundation and NIH research grants focused on clinical neurogenetics. He held senior leadership positions in genomic medicine at the federal and state governments including the National Institute of Health (NIH) and the New York State Department of Health (NYSDOH). At NIH he was part of the Human Genome Project and teams that initiated the first-in-human enzyme replacement and gene therapy clinical trials. He led the Human Genetic Initiative at the NYSDOH. He discovered the genes or loci for several diseases including Parkinson disease, essential tremor, ataxia, intellectual disability (ID), and metabolic disorders. He is a fellow of the American Academy of Neurology with board certifications in Pediatrics by the American Board of Pediatrics and Neurology with Special Qualification in Child Neurology by the American Board of Psychiatry and Neurology. He has authored more than 100 peer-reviewed publications, book chapters, and reviews articles in the field of neurogenetics. He is licensed to practice medicine in MA and NY. Dr. Higgins earned his bachelor’s degree in biology from Marist College and medical degree from New York University. He completed residences in Pediatrics at Children’s Hospital/Harvard Medical School; Adult Neurology at NYU/Bellevue; and Child Neurology at Children’s National Medical Center/George Washington University. He completed a 3-year fellowship program at NIH in neurogenetics and metabolic neurology.
NOW PLAYING
UniQure
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 24, 2026 ·13m
Feb 18, 2026 ·11m
Feb 17, 2026 ·9m
Feb 11, 2026 ·45m
Feb 11, 2026 ·7m